Reimbursement to Determine Future Course of European Continuous Glucose Monitoring Systems Market

The European market for continuous glucose monitoring systems is in its nascent phase. Despite its promising potential, industry participants remain wary due to concerns over reimbursement and acceptance by conservative clinicians. However, the projected integration of continuous glucose monitoring systems with insulin pumps will support market expansion.

Frost & Sullivan (http://www.patientmonitoring.frost.com) finds that the European Continuous Glucose Monitoring Systems Market earned revenues of $14.0 million in 2006 and is likely to reach $ 30 million in 2009.

"Currently in the innovation stage of the product life cycle, the European continuous glucose monitoring systems market is witnessing considerable activity to quickly and effectively meet unmet demand," says Frost & Sullivan Industry Analyst Aarati Ajay. "Attracted by its considerable potential, the industry encompasses an interesting mix of participants ranging from multi-billion dollar global conglomerates such as Abbott Labs, Medtronic, and Johnson & Johnson, to very small technology innovators such as Cybiocare, Sontra, and SpectRx."

Devising a method that involves minimum or no discomfort to the patient, while monitoring blood glucose levels is the biggest challenge facing market participants today. Already, technology initiatives are underway to develop systems that offer reliable and accurate information on glucose levels while causing minimal or no inconvenience to patients. Another major challenge is the cost attached to the use of such devices.

"Currently, there are only three products available in the market and all of them are based on a model in which the sensors need to be changed every few days," explains Ms. Ajay. "Sensors are expensive and add significantly to the total cost of using the system."

Moreover, the inclusion of such systems under the reimbursable category is widely debated since, at present, these devices are useful only to a very small section of the patient population.

A proactive approach to technology development will ensure success in this largely untapped market. Companies able to introduce affordable and user-friendly devices rapidly will capture the majority of this exciting market.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Continuous Glucose Monitoring Systems Market (M011- 56) then send an e-mail to Radhika Menon Theodore- Corporate Communications at This email address is being protected from spambots. You need JavaScript enabled to view it. with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

European Continuous Glucose Monitoring Systems Market is part of the Patient Monitoring Subscription, which also includes research in the following markets: European Market for Telemedicine, European Market for Wireless Patient Monitoring and, European Neurological Monitors Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

Most Popular Now

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

AI Body Composition Measurements can Pre…

Adiposity - or the accumulation of excess fat in the body - is a known driver of cardiometabolic diseases such as heart disease, stroke, type 2 diabetes, and kidney disease...

AI can Strengthen Pandemic Preparedness

How to identify the next dangerous virus before it spreads among people is the central question in a new Comment in The Lancet Infectious Diseases. In it, researchers discuss how...

New AI Tool Scans Social Media for Hidde…

A new artificial intelligence tool can scan social media data to discover adverse events associated with consumer health products, according to a study published September 30th in the open-access journal...

'Future-Guided' AI Improves Se…

In the world around us, many things exist in the context of time: a bird’s path through the sky is understood as different positions over a period of time, and...

Yousif's Story with Sectra and The …

Embarking on healthcare technology career after leaving his home as a refugee during his teenage years, Yousif is passionate about making a difference. He reflects on an apprenticeship in which...

Study Finds One-Year Change on CT Scans …

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease...

New AI Tools Help Scientists Track How D…

Artificial intelligence (AI) can solve problems at remarkable speed, but it’s the people developing the algorithms who are truly driving discovery. At The University of Texas at Arlington, data scientists...

AI Tool Offers Deep Insight into the Imm…

Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily...

New Antibiotic Targets IBD - and AI Pred…

Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets inflammatory bowel diseases...

Highland to Help Companies Seize 'N…

Health tech growth partner Highland has today revealed its new identity - reflecting a sharper focus as it helps health tech companies to find market opportunities, convince target audiences, and...